Hologic Goes Private in $18.3 Billion Private Equity Deal

Hologic Inc. (HOLX) is officially a private company. Its common stock has ceased trading on the Nasdaq and will be delisted following the completion of its acquisition by private equity giants Blackstone and TPG.

The deal, first agreed upon in October, values the women's health company at approximately $18.3 billion. The purchase price of $79 per share represented a substantial 46% premium to Hologic's closing stock price back on May 23, 2025.

With the transaction now closed, shareholders will receive $76 per share in cash immediately. They will also receive a non-tradable contingent value right (CVR) that could be worth up to an additional $3 per share.

This CVR is tied to the performance of Hologic's Breast Health business. It will pay out in two potential installments of up to $1.50 each, contingent on the business hitting specific global revenue milestones in fiscal years 2026 and 2027.

The company also announced a leadership change, with José (Joe) E. Almeida taking over as CEO immediately, succeeding the retiring Stephen MacMillan.

For HOLX shareholders, this transaction delivers immediate and certain value. The 46% premium and cash payout provide a clear exit at an attractive valuation, rewarding long-term investors.

The structure of the deal is noteworthy. The contingent value right (CVR) aligns shareholder interests with the company's future performance even after the buyout. It offers a potential bonus if Hologic's core Breast Health division hits its growth targets under new ownership.

For Hologic as a company, going private marks a major strategic shift. Freed from the quarterly earnings pressures of the public market, it can now focus on long-term innovation and growth initiatives with the deep financial backing of Blackstone and TPG.

This deal signals strong private equity confidence in the healthcare and specifically the women's health sector. Large, established medical technology companies with stable cash flows are seen as attractive assets for leverage and operational improvement away from public scrutiny.

The acquisition also removes a significant player from the public medtech landscape. Investors looking for exposure to the women's health diagnostics and surgical markets will now need to consider other publicly traded competitors.